Q1 Earnings Forecast for PDSB Issued By HC Wainwright

PDS Biotechnology Corporation (NASDAQ:PDSB) – HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for PDS Biotechnology in a research note issued to investors on Tuesday, March 31st. HC Wainwright analyst J. Pantginis expects that the company will earn ($0.15) per share for the quarter. The consensus estimate for PDS Biotechnology’s current full-year earnings is ($1.20) per share. HC Wainwright also issued estimates for PDS Biotechnology’s Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.18) EPS and Q4 2026 earnings at ($0.20) EPS.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PDS Biotechnology in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, PDS Biotechnology presently has an average rating of “Hold” and an average target price of $9.00.

PDS Biotechnology Stock Performance

PDSB opened at $0.64 on Wednesday. The company has a current ratio of 2.09, a quick ratio of 2.09 and a debt-to-equity ratio of 1.26. The company has a market cap of $35.45 million, a price-to-earnings ratio of -0.85 and a beta of 1.20. The company’s 50 day moving average is $0.69 and its 200 day moving average is $0.85. PDS Biotechnology has a 12-month low of $0.51 and a 12-month high of $1.92.

PDS Biotechnology (NASDAQ:PDSB) last released its quarterly earnings results on Monday, March 30th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.06.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Virtu Financial LLC purchased a new position in shares of PDS Biotechnology during the 4th quarter valued at about $25,000. Tempus Wealth Planning LLC increased its holdings in PDS Biotechnology by 29.3% in the 4th quarter. Tempus Wealth Planning LLC now owns 61,800 shares of the company’s stock worth $48,000 after acquiring an additional 14,000 shares in the last quarter. Watts Gwilliam & Co. LLC bought a new stake in PDS Biotechnology during the 2nd quarter worth approximately $73,000. Marshall Wace LLP bought a new stake in PDS Biotechnology during the 2nd quarter worth approximately $91,000. Finally, Jane Street Group LLC purchased a new position in PDS Biotechnology during the second quarter valued at approximately $92,000. Institutional investors own 26.84% of the company’s stock.

PDS Biotechnology Company Profile

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.